Open AccessThe novel ischemia marker ‘ischemia‐modified albumin’ is increased in normal pregnancies
Author(s) -
GUVEN SULEYMAN,
ALVER AHMET,
MENTESE AHMET,
ILHAN F. CEYLAN,
CALAPOGLU MUSTAFA,
UNSAL MESUT A.
Publication year - 2009
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.1080/00016340902777517
Subject(s) - medicine , ischemia modified albumin , ischemia , albumin , cardiology , myocardial ischemia
The aim of this prospective case‐control study was to determine the change in serum maternal ischemia‐modified albumin (IMA) during normal pregnancies. A total of 117 pregnant (first trimester ( n = 24), second trimester ( n = 34), and third trimester ( n = 35)) and non‐pregnant healthy women ( n = 23) were included. Maternal serum IMA, Malondialdehyde (MDA), and albumin levels were measured. Compared with non‐pregnant women, the cross‐sectional mean IMA levels in pregnant women were significantly increased, while the mean serum MDA and albumin levels were significantly decreased throughout pregnancy. Furthermore, a significant negative correlation between serum IMA and albumin levels ( r = −0.354, p <0.001) was found, and there was a weak positive correlation between serum albumin and MDA levels ( r = 0.334, p <0.001). Serum IMA, which has recently been developed as a clinical marker of ongoing myocardial ischemia, appears to be elevated in normal pregnancy. This may be due to the physiologic oxidative stress state of pregnancy.